AbbVie (NYSE: ABBV) today reported its first quarter financial results for the period ended March 31, 2021. Net income for the first
AbbVie Inc.
-(ABBV)
XNYS:ABBV
AbbVie (ABBV) Stock: Here’s what you need to know before investing
AbbVie Inc. (NYSE: ABBV) has long been fighting to delay the entry of generic alternatives to Humira, the pharma giant's flagship product
AbbVie Inc. (ABBV) Q4 2020 Earnings Call Transcript
AbbVie Inc. (NYSE: ABBV) Q4 2020 earnings call dated Feb. 03, 2021. Corporate Participants: Elizabeth Shea -- Vice President of Investor Relations Richard A.
AbbVie (ABBV) Earnings: 4Q20 Key Numbers
AbbVie Inc. (NYSE: ABBV) reported fourth quarter 2020 earnings results today. Worldwide net revenues rose 59.2% year-over-year to $13.8 billion on a
AbbVie (ABBV) to focus more on pipeline as recovery gathers pace
AbbVie, Inc. (NYSE: ABBV) has been recovering steadily from the virus-related slowdown and latest statistics show that the company's performance has improved
AbbVie Inc. (ABBV) Q3 2020 Earnings Call Transcript
AbbVie Inc. (NYSE: ABBV) Q3 2020 earnings call dated Oct. 30, 2020 Corporate Participants: Liz Shea -- Investor Relations Richard A. Gonzalez -- Chairman of the
AbbVie shares gain after Q3 results beat estimates: Infographic
AbbVie (NYSE: ABBV) reported third-quarter 2020 financial results before the regular trading hours on Friday. The pharmaceutical behemoth reported Q3 revenue of
Strong performance of oncology products bode well for AbbVie (ABBV) going forward
AbbVie Inc. (NYSE: ABBV) reported better-than-expected results for the second quarter of 2020 on Friday. The company reported a 26% increase in
AbbVie (ABBV) Q2 2020 results beat estimates; updates FY20 outlook
AbbVie (NYSE: ABBV), which completed the acquisition of Allergan on May 8, 2020, reported second quarter 2020 earnings results today. The company's
COVID-19 favors AbbVie (ABBV) in reporting upbeat Q1 results
AbbVie (NYSE: ABBV), which is expecting to close the acquisition of Allergan in this month, reported its first quarter 2020 earnings results
AbbVie Inc (NYSE: ABBV) Q1 2020 Earnings Call Transcript
AbbVie Inc (ABBV) Q1 2020 earnings call dated May. 01, 2020 Corporate Participants: Liz Shea -- Vice President, Investor Relations Richard A. Gonzalez -- Chairman of
A visual dashboard of AbbVie’s Q1 2020 earnings results
AbbVie (NYSE: ABBV) reported its first quarter 2020 earnings results, which surpassed the market's views. Adjusted EPS of $2.42 and revenue of
AbbVie Inc (NYSE: ABBV) Q4 2019 Earnings Call Transcript
AbbVie Inc (NYSE: ABBV) Q4 2019 Earnings Conference Call February 07, 2020 Corporate Participants: Liz Shea -- Vice President of Investor Relations Richard A. Gonzalez -- Chairman
Fresh hope for Covid-19 patients as AbbVie (ABBV) leads studies on HIV drug
For some of the leading drugmakers, currently, the first priority is to find an effective treatment for Covid-19, which was declared a
AbbVie’s Q4 results beat expectations
AbbVie (NYSE: ABBV) topped revenue and earnings expectations for the fourth quarter of 2019, allowing the stock to gain over 3% in
AbbVie (ABBV) Q4 earnings preview: Generic competition might weigh on results
With only a few weeks left for closing the high-value acquisition of Allergan, AbbVie (NYSE: ABBV) is busy doing the groundwork for
AbbVie (NYSE: ABBV) Q3 profit dips 31% but beats estimates
AbbVie Inc. (NYSE: ABBV) reported a 31% dip in earnings for the third quarter of 2019 due to higher costs and expenses.
Will Allergan-AbbVie merger be intercepted
Allergan plc (NYSE: AGN) continued to dominate in the tissue expander market as the demand for plastic surgeries is increasing from the
AbbVie tops Q2 views; lifts FY19 earnings outlook
AbbVie's (NYSE: ABBV) earnings and revenue for the second quarter of 2019 surpassed Wall Street's estimates. AbbVie reported adjusted EPS of $2.26
What to expect from AbbVie Q2 earnings
AbbVie (NYSE: ABBV) is scheduled to report its earnings results for the second quarter of 2019 on Friday before the market opens.
M&A alert: AbbVie agrees to acquire Allergan for $63 billion
Confirming reports published by Wall Street Journal earlier today, pharmaceutical giant Abbvie (NYSE: ABBV) said it would acquire Irish competitor Allergan (NYSE: